300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
CleanTech
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Recruiting
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Web3
Medical
Theatre
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Brazil
LATAM
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Bangladesh
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Bolivia
Estonia
Bahamas
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Lithuania
Honduras
Iceland
Cambodia
Israel
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Narya Capital, VC Fund

Narya Capital

VC Fund

Ohio, United States

Narya Capital is a VC fund in Ohio focused on Health Care and Biotechnology. Narya is a thesis-driven, early-stage venture capital firm based in Ohio. Our LPs include some of the most successful investors, entrepreneurs, innovators and institutions in the world. We invest long term capital in people who use technology to solve significant challenges.

Total investments:
30
Last investment:
Lead investor:
13%
Fund size:
$93M
Last fund:

Last updated:

Industries Narya Capital invests in

Health CareBiotechnologyLife ScienceArtificial IntelligenceAgTech

Stages Narya Capital invests in

Series BSeries ASeries CSeedVenture - Series Unknown

Countries Narya Capital invests in

United StatesCanada

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 5 (17%)
  • Biotechnology 5 (17%)
  • Life Science 3 (10%)
  • Artificial Intelligence 3 (10%)
  • AgTech 2 (7%)
See all 40 industries →

Stage

  • Series B 7 (23%)
  • Series A 6 (20%)
  • Series C 5 (17%)
  • Seed 4 (13%)
  • Venture - Series Unknown 4 (13%)
See all 7 stages →

Country

  • United States 14 (47%)
  • Canada 1 (3%)

Team

NameTitleInvestmentsLinksEmail
Colin Greenspon
Colin Greenspon Co-Founder & Partner
Co-Founder & Partner Total investments: 10
Find email
Falon Donohue
Falon Donohue Partner
Partner Total investments: 2
Find email
James David Vance
James David Vance Co-Founder and Partner
Co-Founder and Partner Total investments: 11
Find email

Investments

CompanyDescriptionRoundLinks
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA. $135M / Venture - Series Unknown / Jun 10, 2026
Reprogram Biosciences is a biotechnology company that develops cancer treatment with cell reprogramming technology. $5M / Seed / May 26, 2026
True Anomaly develops space security technologies, including spacecraft, software platforms, and mission systems for orbital operations. The company builds satellites and autonomous systems that support monitoring, maneuvering, and coordination in space environments. Its offerings include simulation tools and mission planning software that helpoperators model scenarios and manage on-orbit activities. The organization also provides hardware and integrated systems that enable responsive deployment and control of space assets. Its work focuses on supporting government and commercial missions that require situational awareness and operational capabilities beyond Earth. $600M / Series D / Apr 28, 2026
Chapter provides a technology-enabled advisory platform that helps individuals navigate Medicare and retirement-related healthcare decisions. The company offers access to licensed advisors who guide users through plan selection, enrollment timing, and coverage evaluation based on individual needs and preferences. It uses data and software tools tocompare Medicare plans across multiple insurance providers, enabling users to review options and understand cost, coverage, and benefits. It supports decision-making by analyzing plan details and presenting recommendations that align with a user’s healthcare requirements and financial considerations. Its services include ongoing support after enrollment, helping individuals manage their coverage and make adjustments when necessary. The platform also provides digital tools, such as applications for tracking healthcare benefits and accessing over-the-counter allowances.Chapter collaborates with financial institutions, healthcare providers, and content platforms to integrate Medicare guidance into broader client and patient services. It delivers advisory support through partnerships, enabling organizations to offer healthcare coverage guidance as part of their existing offerings. The company combines advisory services with data analysis to simplify complex insurance decisions and assist users in understanding available Medicare options. Its operations focus on improving transparency in plan comparisons and supporting individuals throughout different stages of retirement healthcare planning. $100M / Series E / Apr 09, 2026
Valinor Enterprises develops technology solutions addressing operational challenges for defense customers. $54M / Series A / Jan 08, 2026
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. $78M / Series B / Oct 16, 2025
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. $320.8M / Series D / Aug 15, 2025
Atomic Industries is a computational manufacturing company building an AI-powered tool and die maker. $25M / Series A / Jun 26, 2025
True Anomaly develops space security technologies, including spacecraft, software platforms, and mission systems for orbital operations. The company builds satellites and autonomous systems that support monitoring, maneuvering, and coordination in space environments. Its offerings include simulation tools and mission planning software that helpoperators model scenarios and manage on-orbit activities. The organization also provides hardware and integrated systems that enable responsive deployment and control of space assets. Its work focuses on supporting government and commercial missions that require situational awareness and operational capabilities beyond Earth. $260M / Series C / Apr 30, 2025
Chapter provides a technology-enabled advisory platform that helps individuals navigate Medicare and retirement-related healthcare decisions. The company offers access to licensed advisors who guide users through plan selection, enrollment timing, and coverage evaluation based on individual needs and preferences. It uses data and software tools tocompare Medicare plans across multiple insurance providers, enabling users to review options and understand cost, coverage, and benefits. It supports decision-making by analyzing plan details and presenting recommendations that align with a user’s healthcare requirements and financial considerations. Its services include ongoing support after enrollment, helping individuals manage their coverage and make adjustments when necessary. The platform also provides digital tools, such as applications for tracking healthcare benefits and accessing over-the-counter allowances.Chapter collaborates with financial institutions, healthcare providers, and content platforms to integrate Medicare guidance into broader client and patient services. It delivers advisory support through partnerships, enabling organizations to offer healthcare coverage guidance as part of their existing offerings. The company combines advisory services with data analysis to simplify complex insurance decisions and assist users in understanding available Medicare options. Its operations focus on improving transparency in plan comparisons and supporting individuals throughout different stages of retirement healthcare planning. $75M / Series D / Apr 16, 2025
See all 30 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
CleanTech
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Recruiting
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Web3
Medical
Theatre
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Brazil
LATAM
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Bangladesh
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Bolivia
Estonia
Bahamas
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Lithuania
Honduras
Iceland
Cambodia
Israel
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Narya Capital invest in?

Narya Capital invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series B and Series A stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Narya Capital?

Public channels for Narya Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Narya Capital?

The team at Narya Capital includes Colin Greenspon (Co-Founder & Partner), Falon Donohue (Partner) and James David Vance (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Narya Capital Narya Capital Find emails